Identifying proteins targeted by specific enzymes involved in protein degradation
Developing computational methods to identify of endogenous substrates of E3 ubiquitin ligases and molecular glue degraders
This study is looking at how certain enzymes help the body decide which proteins to break down, especially in diseases like cancer and autoimmune disorders, to find new ways to improve treatment for patients.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Drexel University NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-10930694 on NIH RePORTER |
What this research studies
This research focuses on understanding how certain enzymes, known as E3 ubiquitin ligases, identify and tag proteins for degradation in the body. By developing computational methods, the project aims to uncover the specific proteins that these ligases target, especially in the context of diseases like cancer and autoimmune disorders. The approach involves analyzing genetic mutations and small molecules that can alter the behavior of these ligases, potentially leading to new therapeutic strategies. Patients may benefit from insights gained about how to manipulate these pathways for better disease management.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals with autoimmune diseases or cancers that may be influenced by E3 ligase activity.
Not a fit: Patients with conditions unrelated to protein degradation or those not affected by E3 ligase dysregulation may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments for diseases by targeting specific proteins for degradation.
How similar studies have performed: Other research has shown promise in targeting E3 ligases for therapeutic purposes, indicating that this approach has potential for success.
Where this research is happening
Philadelphia, United States
- Drexel University — Philadelphia, United States (Active)
Researchers
- Principal investigator: Mischley, Victoria — Drexel University
- Study coordinator: Mischley, Victoria
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.